"The thrill of victory and the agony of defeat."

That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (NASDAQ: CRSP) and (NYSE: PFE) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.

But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the arguments for CRISPR Therapeutics and Pfizer, respectively.

Continue reading

Source Fool.com